There are 15 trials with MEK inhibitors and lung cancer, 14 trials with MEK inhibitors and pancreatic cancer, 10 trials with MEK inhibitors and colon cancers, 4 trials with MEK inhibitors and leukemias, 4 trials with MEK inhibitors and HCC, 4 trials with MEK inhibitors and brain cancers, 2 trials with MEK inhibitors and breast cancer and interestingly 0 trials with MEK inhibitors and prostate cancer. This evidence concerns the gene MAP2K7 and prostate cancer.